Skip to main content

Table 2 Percentage of the population using substances (ATC level 4) according to polypharmacy status

From: Polypharmacy in older patients with chronic diseases: a cross-sectional analysis of factors associated with excessive polypharmacy

Substances

All subjects

Polypharmacy < 10 substances

Excessive polypharmacy ≥10 substances

n

(%)

n

(%)

n

(%)

C10AA

HMG CoA reductase inhibitors

2479

63.5

999

60.8

1480

65.5

A02BC

Proton pump inhibitors

2328

59.6

837

50.9

1491

66.0

C07AB

Beta blocking agents, selective

2240

57.4

909

55.3

1331

58.9

B01AC

Platelet aggregation inhibitors excl. Heparin

1952

50.0

762

46.4

1190

52.7

C09AA

ACE Inhibitors, plain

1751

44.9

792

48.2

959

42.4

C03CA

Sulfonamides, plain

1715

43.9

569

34.6

1146

50.7

C08CA

Dihydropyridine derivates

1611

41.3

658

40.0

953

42.2

C09CA

Angiotensin II antagonists, plain

1355

34.7

505

30.7

850

37.6

C03AA

Thiazides, plain

1354

34.7

555

33.8

799

35.4

A11CC

Vitamin D and analogues

1120

28.7

345

21.0

775

34.3